✦ LIBER ✦

Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

✍ Scribed by Ji-Won Kim; Byung-Su Kim; Soo-Mee Bang; Inho Kim; Dong Hwan Kim; Won Seog Kim; Deok-Hwan Yang; Je-Jung Lee; Je-Hwan Lee; Jin Seok Kim; Sang-Kyun Sohn; Ho-Young Yhim; Jae-Yong Kwak; Sung-Soo Yoon; Jong Seok Lee; Seonyang Park; Byoung Kook Kim; on behalf of the Korean Society of Blood and Marrow Transplantation

Publisher: Springer
Year: 2011
Tongue: English
Weight: 197 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1227-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Outpatient reduced-intensity allogeneic

Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method

✍ Cesar Homero Gutiérrez-Aguirre; Guillermo Ruiz-Argüelles; Olga Graciela Cantú-Ro 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 158 KB

Rituximab long-term maintenance therapy

Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma

✍ Frank Neumann; Stefani Harmsen; Simona Martin; Ralf Kronenwett; Mustafa Kondakci 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 96 KB

Therapeutic results in patients with rel

Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation

✍ Felicetto Ferrara; Assunta Viola; Carolina Copia; Ettore Mariano Schiavone; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract Forty patients with relapsed diffuse large B cell lymphoma (DLBCL) autografted in partial response (PR) (__n__ = 23) or in refractory relapse (RR) (__n__ = 17) achieved complete remission (CR) after autologous stem cell transplantation (ASCT). Salvage treatment consisted of ifosphamide,

Estimating late adverse events using com

Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients

✍ Rodrigo Ruiz-Soto; Guillaume Sergent; Christian Gisselbrecht; Jerome Larghero; M 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

Rituximab therapy increased post-transpl

Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation

✍ Ming-Yang Lee; Tzeon-Jye Chiou; Liang-Tsai Hsiao; Muh-Hwa Yang; Pang-Chan Lin; S 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 111 KB

Phase II study of bryostatin 1 and vincr

Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant

✍ Paul M. Barr; Hillard M. Lazarus; Brenda W. Cooper; Mark D. Schluchter; Ashok Pa 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views